

February 20, 2025

CALCITONIN GENE-RELATED PEPTIDE RECEPTOR (CGRP) ANTAGONIST AGENTS, PROPHYLAXIS CLINICAL PRIOR AUTHOR

BACKGROUND

In August 2024, the Vendor Drug Program (VDP) published a recent version of the Calcitonin Gene-Related Peptide (CGRP) Antagonists, Prophylaxis criteria document approved by the Drug Utilization Review Board on July 26, 2024.

ACTION

Regarding the implementation of CGRP Antagonist Agents, Prophylaxis, clinical prior authorization is optional for MCOs. MCOs implementing this prior authorization must use the most recent July 26, 2024 version for their approval criteria. In the revised step, requiring prior therapy with first-line agents was removed.

NOTE

MCOs should refer to the Clinical Prior Authorizations for Managed Care page for the most current version of clinical prior authorization criteria guides. Links in other documents, such as the Preferred Drug List, may not be current as those documents are updated only at certain times within the year.

RESOURCES

- Clinical Prior Authorizations for Managed Care
 - txvendordrug.com/formulary/clinical-prior-authorizations-managed-care
- Calcitonin Gene-Related Peptide Receptor (CGRP) Antagonists, Prophylaxis criteria guide
 - paxpress-txpa.acentra.com/cgrpchronicpdg.pdf